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Background: The most common human prion disorder
is Creutzfeldt–Jakob disease (CJD); it includes sporadic,
familial, iatrogenic, and variant subtypes. Diagnostic
tests aim at detection with the highest specificity of very
small deposits of abnormal prion protein (PrP).
Methods:We used immunoquantitative PCR (iqPCR) to
detect proteinase K–resistant PrP (PrPRes) in tissue from
the middle frontal gyrus of 7 patients with sporadic CJD
and 7 non-CJD cases. We compared iqPCR with routine
optimized ELISA, Western blotting, and immunohisto-
chemical analyses.
Results: The 4 methods showed similar 100% sensitivity
and specificity for the diagnosis of CJD. Along with
high specificity, however, iqPCR had a threshold for
PrPRes detection at least 10-fold lower than that of the
classic ELISA.
Conclusions: iqPCR is a new method for PrPRes detec-
tion that combines 100% specificity with a detection
threshold at least 10-fold lower than classic techniques.
This method may improve the detection of minute
PrPRes deposits in tissues and body fluids and thus be
useful for diagnostic and sterilization applications.
© 2005 American Association for Clinical Chemistry
Transmissible spongiform encephalopathies (TSEs)4 are
disorders that involve proteins called prions (1 ). The
cellular prion protein (PrPC) is a 33- to 35-kDa glycopro-
tein attached to the cell membrane by a glycosylphos-
phatidylinositol anchor; it is produced in most cell types,
mainly by neurons (2 ). Pathogenic PrP results from a
posttranslational modification of the cellular template (3 ).
This nonconventional transmissible agent accumulates in
the central nervous system (CNS), where it is associated
with spongiosis, gliosis, and neuronal loss. It has a high
-sheet content compared with PrPC, which has more
-helices (4 ). This conformational change of -helices into
-sheets confers particular physicochemical properties to
the pathogenic PrP, such as solubility in nonionic deter-
gents and partial proteinase K (PK) resistance (5 ). Detec-
tion of PK-resistant PrP (PrPRes) is the basis for TSE
diagnostic tests.
Prion diseases are fatal neurodegenerative disorders.
Clinical features include dementia, cerebellar ataxia, mo-
tor dysfunction, and behavioral changes. Among animal
prion diseases, bovine spongiform encephalopathy (BSE)
has been studied extensively. This disease reached epi-
demic proportions in the United Kingdom in the 1990s
and threatens human health with the emergence of a
variant form of Creutzfeldt–Jakob disease (vCJD) (6 ).
Other human TSEs include sporadic and iatrogenic forms
of CJD, Gerstmann–Stra¨ussler–Scheinker syndrome, kuru,
and fatal familial insomnia (7 ). The sporadic cases repre-
sent 85% of all human prion diseases and are thought to
be caused by spontaneous conformational changes of PrP.
Familial forms are inherited in an autosomal dominant
mode through germline mutations of the PrP gene, PRNP.
Iatrogenic forms have occurred as a result of exposure to
contaminated neurosurgical instruments, dura mater
grafts, or transfer of human cadaver pituitary hormones
(8 ). Kuru presented as an epidemic in Papua, New
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Guinea, in the 1960s and has been linked to cannibalistic
rituals. vCJD is zoonotically related to BSE (9, 10). An
allelic polymorphism of codon 129 of human PRNP
modulates disease susceptibility and clinicopathologic
phenotype in CJD (11 ).
Detection of CJD is not possible at the preclinical stage.
In symptomatic patients, clinical presentation, electroen-
cephalographic features, brain imaging techniques (12 ),
and 14-3-3 protein analysis in cerebrospinal fluid (13 )
may indicate CJD. Definitive diagnosis requires neuro-
pathologic examination of the brain (14 ). The recent
observation of an increase in sporadic CJD incidence and
reports of possible blood transmission of vCJD (15, 16) are
strong incentives for the development of highly sensitive
methods to detect PrPRes.
In this study, we assessed the sensitivity and specificity
of immunoquantitative PCR (iqPCR) for the detection of
PrPRes in the brains of CJD patients and compared sample
analysis results obtained by iqPCR, immunohistochemis-
try (IHC), ELISA, and Western blotting.
Materials and Methods
case selection
At postmortem examination, brain tissue samples were
obtained from 7 patients with sporadic CJD and 7 control
individuals. Neuropathologic diagnosis of CJD was based
on extensive microscopic review of frontal, temporal,
parietal, and occipital cortices; the cingulum, hippocam-
pus, and amygdala; central gray matter; subthalamic
nuclei; the brainstem; and the cerebellum. We selected 7
cases with characteristic clinical, histologic, and IHC
features of sporadic CJD. Patient age at the time of death
ranged from 57 to 81 years (mean, 68 years). Five patients
presented with rapidly progressive dementia, 1 with
cerebellar ataxia (CJD), and 1 with paresis and paresthesia
of the left leg (patient CJD3). All patients later developed
myoclonic movements and had abnormal electroencepha-
lograms with periodic sharp wave complexes. There was
no family history of demential disorders. Neuropatho-
logic features were characteristic of spongiform encepha-
lopathy, various degrees of spongiform changes, neuronal
loss, and gliosis (14 ). In all 7 cases, IHC analysis with 3
monoclonal antibodies (3F4, KG9, and 4F7) confirmed the
presence of PrPRes deposits, a finding that fulfills current
neuropathologic criteria for definite CJD diagnosis
(14, 17). The 7 control individuals included 4 patients
with neurodegenerative brain diseases and 3 patients
with healthy brain histology who died of nonneurologic
disorders. This study was approved by the Ethical Com-
mittee of the Faculty of Medicine of the University of
Lie`ge. The clinical, histologic, and immunohistologic data
are summarized in Table 1.
ihc
For each case, sections (5-m thickness) were cut from
formalin-fixed, formic acid–treated, paraffin-embedded
brain tissue representative of the middle frontal gyrus
cortex, an area where diagnostic surgical biopsies for CJD
have been performed (18, 19); the primary visual cortex
(area striata); and the hemispheric cerebellar cortex. Sec-
tions were hydrated with graded alcohols and incubated
in H2O2 (3 mL/L) for 15 min. They were left in formic acid
(96% by weight; Sigma) for 15 min, washed twice in
running tap water (10 min each time), and autoclaved for
11 min at 126 °C in citrate buffer (pH 6) for antigen
retrieval. PrPC digestion was carried out for 5 min in 10
mg/L PK (Sigma) diluted in phosphate-buffered saline
(PBS; 8 mmol/L Na2HPO4  2 H2O, 1.5 mmol/L KH2PO4,
Table 1. Histologic and immunohistologic data for study patients.
Case Age, years Sex Neurologic presentation Final (postmortem) diagnosisa
Controls
C1 71 M No neurologic disease Myocardial infarction
C2 74 M No neurologic disease Esophageal squamous cell carcinoma
C3 15 M No neurologic disease Sudden death (cardiac arrhythmia)
C4 82 M Dementia FTD-MNDb
C5 81 F Dementia Alzheimer disease
C6 68 M Dementia Alzheimer disease
C7 51 M Dementia FTDP-17
CJD patients
CJD1 73 F Rapidly progressive dementia Sporadic CJD
CJD2 57 M Rapidly progressive dementia Sporadic CJD
CJD3 62 M Paresis and paresthesia in left lower limb Sporadic CJD
CJD4 81 M Cerebellar ataxia Sporadic CJD
CJD5 71 F Rapidly progressive dementia Sporadic CJD
CJD6 70 M Rapidly progressive dementia Sporadic CJD
CJD7 63 F Rapidly progressive dementia Sporadic CJD
a Clinical data for diagnosis: for Alzheimer disease, diagnosis was based on CERAD criteria (26); for sporadic CJD, diagnosis was based on neuropathologic criteria
updated by Budka et al. (17) and used by the WHO reviewed by Budka (14); diagnoses of frontotemporal dementia with motor neuron disease and frontotemporal
dementia with parkinsonism linked to chromosome 17 were based on criteria proposed by the Work Group on Frontotemporal Dementia and Pick’s Disease (27).
b FTD-MND, frontotemporal dementia with motor neuron disease; FTDP-17, frontotemporal dementia with parkinsonism linked to chromosome 17.
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137 mmol/L NaCl, 3 mmol/L KCl), as described previ-
ously (20 ). Sections were blocked in normal rabbit serum
(1:10 dilution; Vector) for 1 h, rinsed, incubated overnight
at 4 °C with 3 primary monoclonal antibodies against PrP
[3F4 (residues 109–111 of the human form; 1:50 dilution;
Dako), KG9 (residues 140–180 of the human form; 1:250
dilution; TSE Resource Center), and 4F7 (residues 140–
160; 1:1000 dilution; Roboscreen)], and then incubated
with secondary antibodies (ENVISION; Dako) for 30 min.
Immunoreactivity was visualized with 3,3-diaminoben-
zidine (DAB; Dako). Negative controls were incubations
in which the primary antibody was omitted.
elisa, western blots, and iqPCR
Sample preparation. For ELISA, Western blots, and iqPCR,
human PrP was extracted by routine optimized purifica-
tion (Bio-Rad Platelia BSE Kit; cat. no. 355-1102) from
frozen brain tissue blocks representative of the middle
frontal gyrus. Briefly, nervous tissue (350 mg) was
homogenized for 45 s, and 500 L of this homogenate was
treated with PK for 14 min at 37 °C in buffer A. After the
reaction was stopped and 500 L of buffer B was added,
tubes were centrifuged for 5 min at 20 000g. Immunode-
tection was performed on pellets previously resuspended
in buffer C1 and heated 5 min at 100 °C in buffer C1. The
positive control was a recombinant cellular human prion
protein (Roboscreen).
ELISA. Plastic well surfaces of Immunostrips (Maxisorp;
Nunc) or Robostrips® (Roboscreen) were precoated with
10 mg/L monoclonal antibody 1E5 (Roboscreen) at
6–8 °C overnight. The next day, the wells were emptied,
washed 3 times (washing buffer: 50 mmol/L Tris, 150
mmol/L NaCl, 0.5 mL/L Tween 20), blocked for 1 h with
200 L of blocking buffer (washing buffer containing 10
g/L bovine albumin), and rinsed again. The precoated
Immunostrips and Robostrips were then sealed in flat
bags and stored at 4–6 °C until use. The precoated,
saturated strips were incubated with different dilutions
(crude and 1:5, 1:10, 1:50, 1:100, 1:500, 1:1000, and 1:5000
dilutions) of human brain extract for 1 h at room temper-
ature. The calibrator (human recombinant PrP) was incu-
bated in the wells at concentrations from 10 mg/L to 10
ng/L. The strips were washed with PBS and then incu-
bated with the biotinylated detection antibody 4F7 (1
mg/L; Roboscreen) for 1 h at room temperature. The
wells were again washed 3 times with PBS containing 1
mL/L Tween and 3 times with PBS containing 15 g/L
bovine serum albumin. Peroxidase-conjugated streptavi-
din (Dako; diluted 1:7500) was added to each well and
incubated for 30 min at room temperature. After 5 washes
in PBS, the residual peroxidase activity was measured by
means of chromogenic reaction with a solution containing
equal amounts, by volume, of 3,3,5,5-tetramethylbenzi-
dine and H2O2 (BD PharMingen). After incubation for 30
min in the dark at room temperature, the reaction was
stopped by addition of 1 mol/L H2SO4. The absorbance of
the reaction mixture was measured at 450 nm (A450 nm)
with an automatic reader instrument (BioTek ELX800NB).
iqPCR. The iqPCR procedure (Fig. 1) was identical to that
for ELISA up to the addition of the biotinylated detection
antibody 4F7. iqPCR was carried out in Robostrips pre-
coated and saturated with optimized buffer. At each step,
the incubation volume was 50 L/well, as it was for the
ELISA. The calibrator was used in iqPCR at a dilution
range from 1 mg/L to 1 ng/L. After a 1-h incubation with
detection antibody, the strips were washed 3 times with
PBS containing 1 mL/L Tween and 3 times with PBS
containing 15 g/L bovine serum albumin. Briefly, recom-
binant streptavidin (Roche) was preincubated for 45 min
at 4 °C with biotinylated reporter DNA in a 1:2 molar ratio
(21, 22). The resulting streptavidin–DNA complex was
then added to the wells and incubated for 30 min at room
temperature. The strips were washed 5 times with PBS
and 10 times with distilled water, and then were subjected
to PCR. Amplification was carried out in an ABI PRISM
7700 Sequence Detection System (Applied Biosystems)
under the following conditions: 25 L of SYBR Green PCR
Master Mix (Applied Biosystems), 0.3 M each primer,
and 19 L of water in a total volume of 50 L. The
temperature program was as follows: 10 min at 95 °C,
followed by 40 PCR cycles of denaturation at 95 °C for 15 s
and 60 °C for 1 min for the annealing and extension
phases.
SYBR Green is a dye that gives a fluorescence peak
when it is intercalated in double-stranded DNA. Ampli-
fication curves were analyzed with Sequence Detection
System software (Applied Biosystems), and the baseline
(threshold) was determined to avoid background signals.
The intersection between this threshold and the amplifi-
cation curve, the cycle threshold (Ct), was plotted on a
graph vs the sample dilution.
The reporter double-stranded DNA (EMBL sequence
accession no. AX133313) used is original in that it was
built by association of 2 DNA fragments from eukaryotic
Fig. 1. Diagram of iqPCR.
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and prokaryotic origin (21, 22). The primers were de-
signed with Primer Express Software, Ver. 1.0 (Applied
Biosystems): forward primer, 5-AAGCCTTGCAGGA-
CATCTTCA-3; reverse primer, 5-GCCGCCAGTGTGA-
TGGATAT-3.
Western blots. For Western blots, after the purification
protocol, samples were boiled in loading buffer (Bio-Rad)
and subjected to electrophoresis in 12% Tris-glycine gels
(10 L of protein extract and 10 L of 2-concentrated
loading buffer per well). Proteins were then blotted on
polyvinylidene fluoride (PVDF) membranes that had
been blocked overnight at 4 °C with the ECLTM Advance
Blocking Agent (Amersham Biosciences). Samples were
incubated with biotinylated 4F7 (0.1 mg/L) in a solution
containing 2 g/L ECL Advance Blocking Agent in Tris-
buffered saline containing 1 mL/L Tween for 1 h at room
temperature on an orbital shaker. After washing, the
membrane was incubated with peroxidase-conjugated
streptavidin (Dako; diluted 1:7500) for 1 h at room tem-
perature. Specific bands of prion proteins were revealed
by ECL Advance Western blot detection reagents and
visualized with a ChemiDoc digital imager (Bio-Rad).
Results
ihc
No PrP deposits were detected in the CNS tissue of the 7
control individuals. By contrast, in the tissue samples
from the 7 patients with sporadic CJD, PrPRes deposition
was demonstrated by incubation of monoclonal antibod-
ies 3F4 and KG9 with sections from the primary visual
cortex and cerebellar cortex.
Spongiform changes, neuronal loss, and gliosis were
present in all frontal cortex samples from the 7 patients
with sporadic CJD (CJD1 to -7), although with various
intensities. As shown in Table 2, changes were mild in
patient CJD3, moderate in patients CJD2, CJD4, CJD5, and
CJD6, and severe in patients CJD1 and CJD7.
Using KG9, we identified PrPRes deposits in the frontal
cortex of all 7 cases. This result is in accordance with
the high sensitivity of KG9 reported by others (20 ). The
pattern of PrPRes deposition was patchy/perivacuolar in
patients CJD1, CJD5, and CJD6; the pattern was synaptic
in the 4 remaining cases and particularly mild and focal in
patients CJD2, CJD3, and CJD4. The antibody 3F4 de-
tected PrPRes deposits in 6 of 7 cases, with the samples
from patient CJD5 remaining negative. The pattern of
deposition was patchy/perivacuolar in patients CJD1 and
CJD6 and focal/synaptic in the 4 other cases (Fig. 2).
Immunoreactivity for 4F7 was observed in 4 of 7 cases
(CJD1, CJD3, CJD4, and CJD6).
western blots
The different protein extracts from the 14 study patients
were tested by Western blotting to check for the presence
of PrPRes. No signal was detected in non-CJD patients,
whereas PrPRes was detected in all CJD samples, with
different loads, in correlation with the ELISA results. As
shown in Fig. 3, high PrPRes concentrations were observed
in cases CJD1 and CJD2. The lowest PrPRes load was
observed in patient CJD4.
standard immunodetection
The human recombinant PrP calibrator was tested by
ELISA and iqPCR in the same way as the brain samples.
Calibration curves were plotted from a dilution range of
the protein for both methods. The detection limits were
1 g/L (defined as 3  the value for the control  3 
0.046) for the ELISA and 100 ng/L for iqPCR. Detection
limits of the iqPCR method were defined as the concen-
tration giving a difference of 2.2 Ct (2 SD) lower than that
given for the negative control without PrP (Ct  30); the
cutoff thus was 27.8 cycles (Fig. 4). The lower limit of
detection for human recombinant PrP was therefore 10-
fold lower than that of the ELISA technique.
elisa
As shown by the A450 nm values plotted vs sample dilution
(Fig. 5), all control human brains were clearly negative:
absorbance was close to 0. In samples from CJD brains,
maximum absorbance values were variable (Fig. 5B). In
general, the detection limit for PrPRes was between dilu-
tions 1:10 and 1:100. The detection limit in this case was
defined as the lowest concentration giving an absorbance
3 times higher than that given by the controls. As with
Table 2. Histologic and immunohistologic features of the frontal cortex in CJD patients.
Case Histology (spongiform changes)
IHCa
KG9 3F4 4F7
CJD1 Severe Patchy/perivacuolar  Patchy/perivacuolar  Patchy/perivacuolar 
CJD2 Moderate Focal/synaptic  Focal/synaptic  Negative
CJD3 Mild Focal/synaptic  Focal/synaptic  Focal/synaptic 
CJD4 Moderate Focal/synaptic  Focal/synaptic  Focal/synaptic 
CJD5 Moderate with coalescent vacuoles Patchy/perivacuolar  Negative Negative
CJD6 Moderate with coalescent vacuoles Patchy/perivacuolar  Patchy/perivacuolar  Patchy/perivacuolar 
CJD7 Severe Synaptic  Focal/synaptic  Negative
a , mildly positive;  , moderately positive;   , strongly positive.
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Western blotting, only low concentrations of PrPRes were
retrieved from patient CJD4.
iqPCR
iqPCR results, plotted as the Ct vs sample dilution (Fig. 6)
indicated that there was no significant nucleic amplifica-
tion when the Ct was close to 40. For PK-treated non-CJD
samples, the Ct was 30 for all dilutions (Fig. 6A), which
indicates that this is the background value. For all 7 CJD
patients, the Ct was dose-dependent (Fig. 6B): the lower
the PrP concentration, the higher the Ct. The detection
limit of iqPCR was much lower than that of ELISA in all
cases. In cases CJD1, CJD2, and CJD5, for example, PrPRes
was detected in the 1:1000 dilution; the iqPCR detection
limit for PrPRes thus was at least 10-fold lower than the
detection limit of the ELISA for all patients (Table 3).
Discussion
In 2004, Cervenakova and Brown (23 ) reviewed screening
tests for the diagnosis of prion diseases, including fluores-
cent correlation spectroscopy, Seprion ligand, conformation-
dependent immunoassay, time-resolved fluorescence spec-
troscopy, and protein misfolding cyclic amplification.
They also commented on immuno-PCR as a promising
method for detecting PrPRes at very low concentrations
(23 ).
In a previous study, we showed that bovine PrPRes can
be detected with very high sensitivity by iqPCR (21 ). This
technology, described previously by Zorzi et al. in patent
WO0131056 (22 ), couples an antibody detection step
similar to an ELISA with nucleic acid amplification by a
real-time PCR procedure. The detection threshold of
iqPCR is lower than classic ELISA for recombinant and
infectious bovine PrP (21 ).
Fig. 2. Microscopic changes in the frontal cortex of
CJD cases.
Tissue from patient CJD1 showed severe changes indicat-
ing spongiform encephalopathy after staining with hematox-
ylin and eosin (A) as well as abundant perivacuolar PrPRes
deposits after staining with antibody 3F4 (B; original mag-
nification, 50), leading to the obvious diagnosis of prion
disease. In patient CJD4 (C), spongiform changes were
mild/moderate, as visualized by staining with hematoxylin
and eosin: true spongiosis (arrows) can be distinguished
from vacuolar artifacts (arrowheads). Sparse deposits of
PrPRes (original magnification, 200) were detected with
antibody 3F4 (D).
Fig. 3. Western blot of PK-treated brain samples from CJD cases and
control cases (each well was loaded with the same amount of protein).
Recombinant human PrP (rec) was used as a positive control (100 ng). The
immunoblots were analyzed by high-sensitivity ECL Advance using biotinylated
anti-PrP monoclonal antibody 4F7 and peroxidase-conjugated streptavidin. Dual
Color molecular mass markers (Bio-Rad), in kDa, are shown on the left.
Fig. 4. Comparison of human recombinant PrP detection by ELISA (Œ),
with a cutoff at A450 nm of 0.13, and iqPCR (E), with a cutoff at Ct 27.8.
Also shown is the negative control without antigen (wo Ag).
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In the present study, we compared iqPCR with cur-
rently used routine methods, such as ELISA, Western
blotting, and IHC, for the diagnosis of sporadic CJD cases.
Each method showed 100% sensitivity and specificity in
our series. With the iqPCR method, however, we detected
the presence of PrPRes at concentrations at least 10-fold
lower than with other methods. Like other PCR tech-
niques, iqPCR is hampered by a nonspecific background
signal (24 ). In our data, the background signal was
probably generated by nonspecific binding of reagents to
the well surface. We have optimized the blocking and
washing steps, however, to maintain an acceptable signal-
to-noise ratio and keep 100% specificity.
Because iqPCR combines 100% specificity with a detec-
tion threshold at least 10-fold lower than that of ELISA,
iqPCR may improve the detection of minute amounts of
PrPRes deposits in tissues and body fluids for diagnostic or
sterilization applications.
Brain biopsies are rarely performed in CJD patients
when diagnosis of treatable alternatives to spongiform
encephalopathy are under serious consideration. In the
series of 55 biopsies reported by Brown et al. (18 ), brain
biopsy was diagnostic in 95% of cases later confirmed by
autopsy. In our cases, changes indicating spongiform
encephalopathy were present in the frontal cortex of all 7
cases, although with mild intensity in 1 case (CJD3). In
another, smaller series, Mahadevan et al. (19 ), using
antibodies KG9 and 3F4, detected PrPRes deposition in
only 5 of 8 brain frontal biopsies from CJD patients. In our
study, by combining the KG9 and 3F4 antibodies with PK
treatment, we detected PrPRes deposits in 7 of 7 and 6 of 7
cases, respectively. In 4 cases (patients CJD2 to -5), how-
ever, deposits were mild and focal, with a synaptic
pattern, and could have been missed on an infracentimet-
ric biopsy. Western blotting was confirmatory in most of
these cases but was inconclusive in 1 (CJD4), for which
ELISA and iqPCR were clearly positive. The main limita-
tion of iqPCR at this stage is the need for fresh or
cryopreserved tissue. We are currently adapting the
method for use on formalin-fixed, paraffin-embedded
material. A recent report (20 ) suggests that well-pre-
served PrPRes can be retrieved in useful amounts from
such formalin-fixed, paraffin-embedded material. The ap-
plication of iqPCR to archival material would allow large
retrospective studies.
A previous report has shown that macaques infected
with extracts of BSE-infected brains have PrPRes in extra-
CNS tissues, such as lymphoreticular tissue in the tonsils,
Peyer’s patches, and the spleen (15 ). Moreover, Glatzel et
al. (25 ), using a special phosphotungstate preconcentra-
Fig. 5. Detection of PrPRes by sandwich ELISA in control cases (A) and
CJD patients (B).
A450 nm is plotted against the protein extract dilutions. Error bars indicate SD
from the means of 3 replicate experiments. The detection cutoff for the ELISA is
A450 nm  0.13.
Fig. 6. Detection of human PrPRes by iqPCR in control cases (A) and CJD
patients (B).
The Ct is plotted vs the sample dilutions (wo PrP, negative control without PrP).
Error bars indicate SD from the means of 3 replicate experiments. The detection
cutoff for the iqPCR assay is Ct 27.8.
Table 3. Summary of the ELISA and iqPCR detection limits:
Lowest dilutions that were above the cutoff values for each
CJD patient.
Case
CJD1 CJD2 CJD3 CJD4 CJD5 CJD6 CJD7
ELISA 100 100 50 10 100 10 50
iqPCR 1000 1000 500 100 1000 100 500
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tion step, found PrPRes in the spleen and muscles of some
patients with sporadic CJD. These reports suggest that
small PrPRes deposits occur outside the CNS in primate
and human TSEs, in both sporadic and variant (BSE-
related) subtypes.
iqPCR may be useful to analyze extra-CNS tissue in
which PrPRes accumulates in prion diseases. As reported
previously (23 ), immuno-PCR is a sensitive method that
enables detection of small amounts of molecules, but it
needs refinement. We have developed an iqPCR method
with real-time analysis to improve the technique and
avoid time-consuming post-PCR handling (21 ). We in-
tend in the future to couple the sensitivity of iqPCR with
prion protein–scrapie form (PrPSc) concentration steps
based on phosphotungstic acid precipitation or other
means to detect PrPSc in very low amounts.
The recently reported suspicion of transmission of
vCJD by blood transfusion (16 ) demonstrates the need for
detection methods allowing certification of totally effec-
tive decontamination procedures for transfusion material,
as well as for neurosurgical and endoscopic instruments.
Monitoring of sterilization effectiveness may represent
another application of iqPCR.
In conclusion, we have developed iqPCR as a new tech-
nique for PrPRes detection. In our study, iqPCR combined
100% specificity with a detection threshold at least 10-fold
lower than that of ELISA. This new method may be useful
for the detection of minute PrPRes deposits in CNS and
extra-CNS tissues, such as body fluids.
We gratefully acknowledge the financial support of this
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